Cite

HARVARD Citation

    Bhreathnach, Ú. et al. (2022). Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia. Leukemia research. p. . [Online]. 
  
Back to record